Our Phase 3 SERENITY-CM study will be initiating in 2023
© 2022 Sollis Therapeutics Inc.
Sollis Therapeutics is a registered trademark of Sollis Therapeutics, Inc.
Design and development by RainCastle Communications
Our Clonidine Micropellet (clonidine hydrochloride extended-release epidural micropellet) investigational treatment is designed to target the source of sciatica pain over time, while also reducing inflammation at the injured nerve.* Our goal is to develop rapid, durable pain relief that allows healing—using a non-opioid, non-steroid medication.
Learn more about clinical trials and review results and publications.
We are currently in the planning stages for upcoming trials. Check back soon for up-to-date information.
* The Sollis Clonidine Micropellet therapy is an investigational treatment for sciatica and has not been approved for use by the FDA.